<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39423791</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Management of vulnerable patients hospitalized for COVID-19 with remdesivir: a retrospective comparative effectiveness study of mortality in US hospitals.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ciae512</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciae512</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 remains a major public health concern, with continued resurgences of cases and substantial risk of mortality for hospitalized patients. Remdesivir has become standard-of-care for hospitalized COVID-19 patients. Given the continued evolution of the disease, clinical management relies on evidence from the current endemic period.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using the PINC AI Healthcare database, effectiveness of remdesivir was evaluated among adults hospitalized with a primary diagnosis of COVID-19 between December 2021 and February 2024. Three cohorts were analysed: adults, elderly (≥65 years), and those with documented COVID-19 pneumonia. Analyses were stratified by oxygen requirements. Patients receiving remdesivir were matched to those not receiving remdesivir using propensity score matching. Cox proportional hazards models were used to examine in-hospital mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">169,965 adults hospitalized for COVID-19 were included, of which 94,129 (55.4%) initiated remdesivir in the first two days of hospitalization. Remdesivir was associated with a significantly lower mortality rate as compared to no remdesivir among patients with no supplemental oxygen charges (NSOc) (aHR [95% CI]: 14-day, 0.75 [0.69-0.82]; 28-day, 0.77 [0.72-0.83]) and among those with supplemental oxygen charges (SOc): 14-day, 0.76 [0.72-0.81]; 28-day, 0.79 [0.74-0.83]) (p&lt;0.0001, for all). Similar findings were observed for elderly patients and those hospitalized with COVID-19 pneumonia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This evidence builds on learnings from randomized controlled trials from the pandemic era to inform clinical practices. Remdesivir was associated with significant reduction in mortality for hospitalized patients including the elderly and those with COVID-19 pneumonia.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mozaffari</LastName><ForeName>Essy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandak</LastName><ForeName>Aastha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5653-435X</Identifier><AffiliationInfo><Affiliation>Certara, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8534-2012</Identifier><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sax</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loubet</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1218-9432</Identifier><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Nimes, Nimes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doi</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9620-2525</Identifier><AffiliationInfo><Affiliation>Fujita Health University School of Medicine, Toyoake, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Alpesh N</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0002-9790-0245</Identifier><AffiliationInfo><Affiliation>University of California, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahuja</LastName><ForeName>Neera</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-1398-3187</Identifier><AffiliationInfo><Affiliation>Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casciano</LastName><ForeName>Roman</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7083-9536</Identifier><AffiliationInfo><Affiliation>Certara, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolditz</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6022-6827</Identifier><AffiliationInfo><Affiliation>Medical Department I, University Hospital Carl Gustav Carus of TU Dresden, Dresden, Saxony, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">antiviral therapy</Keyword><Keyword MajorTopicYN="N">data science</Keyword><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">pneumonia</Keyword><Keyword MajorTopicYN="N">propensity score</Keyword><Keyword MajorTopicYN="N">real-world data</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423791</ArticleId><ArticleId IdType="doi">10.1093/cid/ciae512</ArticleId><ArticleId IdType="pii">7826700</ArticleId></ArticleIdList></PubmedData></PubmedArticle>